Vogenx Inc

VOGXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

20.770.00 (0.00%)

2026-11-12 14:57 CET

Market cap

308.54 USD m

Revenue, TTM

0.00 USD m

Net income, TTM

-4.91 USD m

Free cash flow, TTM

-2.59 USD m

EPS diluted, TTM

-0.33

P/E

Compare

Price

VOGX against its 20 and 50-day averages

2050beatearnings

Patternshover a marker to name it

EPS mean, own scalesmoothed

45.9% under the 52-week high of 38.41 on 18 Sep 2026. 52-week low 12.95 on 12 Aug 2026. Last 15 sessions, 46.3% high to low

Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average

Profile

VOGX

52-week range, 31% of the way up

12.9538.41

Vogenx, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the discovery and development of treatments for serious metabolic and gastrointestinal diseases. The company was founded by James Green, William Wilkison, and Steven Delmar on February 5, 2021 and is headquartered in Raleigh, NC.

IPO	Aug 12, 2026
ATR, 14d	2.67
Rel volume	0.00
Short float	0.78%
Insider own	35.75%
Inst own	13.54%

Snapshot

6 groups

Valuation

Index	-
Market Cap	308.54M
Enterprise Value	226.42M
Income	-
Sales	-
Book/sh	5.52
Cash/sh	5.53
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 12, 2026

Ratios

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.76
P/C	3.76
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	98.33
Current Ratio	98.33
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

Earnings

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.47
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-1568.69%
Sales Q/Q	-
Earnings	Nov 06 AMC
EPS/Sales Surpr.	-422.22% -

Ownership

Insider Own	35.75%
Insider Trans	0.00%
Inst Own	13.54%
Inst Trans	77.82%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	11.42%
SMA50	-8.08%
SMA200	-10.79%
Trades	-

Technical

Shs Outstand	14.86M
Shs Float	9.54M
Short Float	0.78%
Short Ratio	0.48
Short Interest	0.07M
52W High	38.41 -45.93%
52W Low	12.95 60.39%
Volatility	14.20% 15.01%
ATR (14)	2.67
RSI (14)	55.17
Beta	-
Rel Volume	0.00
Avg Volume	155.62K
Volume	0

Performance

Perf Week	5.27%
Perf Month	23.93%
Perf Quarter	47.41%
Perf Half Y	-
Perf YTD	59.77%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.50
Target Price	48.50
Prev Close	20.77
Price	20.77
Change %	0.00%

Peers

Mkt cap

Ticker	Company	Mkt cap
RZLT	Rezolute Inc	384.02M
LXRX	Lexicon Pharmaceuticals Inc	823.69M
AMLX	Amylyx Pharmaceuticals Inc	4.10B
VNDA	Vanda Pharmaceuticals Inc	257.00M
ALT	Altimmune Inc	367.68M
SANA	Sana Biotechnology Inc	692.15M
GPCR	Structure Therapeutics Inc ADR	1.52B
PHAT	Phathom Pharmaceuticals Inc	509.70M
VKTX	Viking Therapeutics Inc	3.59B
XERS	Xeris Biopharma Holdings Inc	3.07B

Ticker

Company

Mkt cap

RZLT

Rezolute Inc

384.02M

LXRX

Lexicon Pharmaceuticals Inc

823.69M

AMLX

Amylyx Pharmaceuticals Inc

4.10B

VNDA

Vanda Pharmaceuticals Inc

257.00M

ALT

Altimmune Inc

367.68M

SANA

Sana Biotechnology Inc

692.15M

GPCR

Structure Therapeutics Inc ADR

1.52B

PHAT

Phathom Pharmaceuticals Inc

509.70M

VKTX

Viking Therapeutics Inc

3.59B

XERS

Xeris Biopharma Holdings Inc

3.07B

Held by

AUM

Ticker	Company	AUM
VXF	Vanguard Extended Market Index ETF	AUM: 30.79B
VTWO	Vanguard Russell 2000 Index ETF	AUM: 16.90B
VTWG	Vanguard Russell 2000 Growth Index ETF	AUM: 1.43B
VTWV	Vanguard Russell 2000 Value Index ETF	AUM: 1.29B
VTHR	Vanguard Russell 3000 Index ETF	AUM: 4.87B

Ticker

Company

AUM

VXF

Vanguard Extended Market Index ETF

AUM: 30.79B

VTWO

Vanguard Russell 2000 Index ETF

AUM: 16.90B

VTWG

Vanguard Russell 2000 Growth Index ETF

AUM: 1.43B

VTWV

Vanguard Russell 2000 Value Index ETF

AUM: 1.29B

VTHR

Vanguard Russell 3000 Index ETF

AUM: 4.87B

Key figures

Revenue, TTM	0.00
Net income, TTM	-4.91
EPS diluted, TTM	-0.33
EBIT, TTM	-1.78
Free cash flow, TTM	-2.59
Gross margin	-%
Operating margin	-%
Net margin	-%
Market cap	308.54
P/E	-
Sales Y/Y, TTM	-

USD millions. TTM from the statement feed.

Quarterly earnings

actual against estimate

Period	Reported	EPS act	EPS est	EPS rep	Sales act	Sales est	Analysts
2026Q3	2026-11-06	-0.470	-0.090	-0.070	0.00	0.00	2
2026Q2	2026-09-02	-0.070	-0.070	-0.026	0.00	0.00	2
2026Q1	2026-06-03	-0.090	-	-0.032	0.00	-	-
2026Q4	-	-	-0.475	-	-	0.00	2

Annual earnings

Period	EPS act	EPS est	EPS rep	Sales act	Sales est
No annual earnings.

Period

EPS act

EPS est

EPS rep

Sales act

Sales est

No annual earnings.

Estimate revisions

last 14 periods

Period	Type	Date	Estimates	Up	Down	Mean	Low	High
2026Q4	S	2026-11-09	1	0	0	0.00	0.00	0.00
2026Q4	S	2026-09-02	1	0	0	0.00	0.00	0.00
2026Q4	S	2026-08-28	1	0	0	0.00	0.00	0.00
2026Q4	R	2026-11-09	1	0	1	-0.33	-0.33	-0.33
2026Q4	R	2026-10-12	1	0	1	-0.33	-0.33	-0.33
2026Q4	R	2026-09-02	1	0	0	-0.24	-0.24	-0.24
2026Q4	R	2026-08-28	1	0	0	-0.24	-0.24	-0.24
2026Q4	E	2026-11-09	2	0	1	-0.48	-0.70	-0.25
2026Q4	E	2026-10-12	2	1	0	0.04	-0.25	0.33
2026Q4	E	2026-09-02	2	0	0	-0.25	-0.25	-0.24
2026Q4	E	2026-09-01	2	0	0	-0.25	-0.25	-0.24
2026Q4	E	2026-08-28	1	0	0	-0.24	-0.24	-0.24
2026Q3	S	2026-09-02	1	0	0	0.00	0.00	0.00
2026Q3	S	2026-08-28	1	0	0	0.00	0.00	0.00

Estimate history

Period	2024	2025
EPS, annual	-0.148	-0.097
EPS, quarterly	-0.024	-0.02	-0.019	-0.032	-0.026	-0.33
Period	Q1 '25	Q2 '25	Q3 '25	Q1 '26	Q2 '26	Q3 '26
Sales, annual	0	0
Period	2024	2025
Sales, quarterly	0	0	0	0	0	0
Period	Q1 '25	Q2 '25	Q3 '25	Q1 '26	Q2 '26	Q3 '26
Shares, annual	14.855	14.855	14.855
Period	2024	2025	MRQ
Shares, quarterly	14.855	14.855	14.855	14.855	14.855	14.855
Period	Q1 '25	Q2 '25	Q3 '25	Q1 '26	Q2 '26	Q3 '26

Income statement, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY
Total Revenue	0.00	0.00	0.00
Cost of Goods Sold Incl. D&A	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00
Selling, General and Administrative Excl. Other	1.78	1.44	2.30
Research and Development	1.08	0.57	1.32
Other Operating Expense	0.00	0.00	0.00
Operating Income	-1.78	-1.44	-2.30
Interest Expense	0.00	-	0.00
Unusual Expense	3.46	0.01	-0.06
Net Income Before Taxes	-4.91	-1.45	-2.20
Income Taxes	0.00	0.00	0.00
Consolidated Net Income	-4.91	-1.45	-2.20
Net Income From Continuing Operations	-4.91	-1.45	-2.20
Net Income	-4.91	-1.45	-2.20
EPS (Recurring)	-0.17	-0.10	-0.15
EPS (Basic, Before Extraordinaries)	-0.33	-0.10	-0.15
EPS (Diluted)	-0.33	-0.10	-0.15
EBITDA	-1.78	-1.44	-2.30
Non-Operating Income (Expense)	0.34	0.01	0.04
Other After Tax Adjustments	0.00	0.00	0.00
Stock Option Compensation Expense	0.00	0.02	0.09
Shares Outstanding	14.86	14.86	14.86
Market Capitalization	308.54	308.54	-

Income statement, quarterly

Currency USD, millions
Metric	2026Q3	2026Q2	2026Q1	2025Q3	2025Q2	2025Q1
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Goods Sold Incl. D&A	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
Selling, General and Administrative Excl. Other	1.78	0.36	0.46	0.30	0.31	0.37
Research and Development	1.08	0.16	0.24	0.12	0.14	0.17
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	-1.78	-0.36	-0.46	-0.30	-0.31	-0.37
Interest Expense	0.00	-	-	0.00	-	0.00
Unusual Expense	3.46	0.03	0.01	-0.02	-0.01	-0.01
Net Income Before Taxes	-4.91	-0.38	-0.48	-0.28	-0.29	-0.36
Income Taxes	0.00	0.00	0.00	0.00	0.00	0.00
Consolidated Net Income	-4.91	-0.38	-0.48	-0.28	-0.29	-0.36
Net Income From Continuing Operations	-4.91	-0.38	-0.48	-0.28	-0.29	-0.36
Net Income	-4.91	-0.38	-0.48	-0.28	-0.29	-0.36
EPS (Recurring)	-0.17	-0.02	-0.03	-0.02	-0.02	-0.02
EPS (Basic, Before Extraordinaries)	-0.33	-0.03	-0.03	-0.02	-0.02	-0.02
EPS (Diluted)	-0.33	-0.03	-0.03	-0.02	-0.02	-0.02
EBITDA	-1.78	-0.36	-0.46	-0.30	-0.31	-0.37
Non-Operating Income (Expense)	0.34	0.00	0.00	0.00	0.00	0.00
Other After Tax Adjustments	0.00	0.00	0.00	0.00	0.00	0.00
Stock Option Compensation Expense	0.00	0.00	-0.00	0.00	0.00	0.00
Shares Outstanding	14.86	14.86	14.86	14.86	14.86	14.86
Market Capitalization	308.54	361.20	-	-	-	-

Balance sheet, annual

Currency USD, millions
Metric	2025FY	2024FY
Cash & Short Term Investments	0.60	0.96
Short Term Receivables	0.00	0.00
Inventories	0.00	0.00
Other Current Assets	0.02	0.01
Total Current Assets	0.62	0.97
Net Property, Plant & Equipment	0.00	0.00
Total Investments and Advances	0.00	0.00
Intangible Assets	0.00	0.00
Other Assets	0.06	0.00
Total Assets	0.68	0.97
Short Term Debt Incl. Current Port. of LT Debt	0.82	0.00
Accounts Payable	0.06	0.11
Other Current Liabilities	0.71	0.29
Total Current Liabilities	1.59	0.40
Long Term Debt	0.00	0.00
Provision for Risks Charges	0.00	0.00
Other Liabilities	0.01	0.07
Total Liabilities	1.60	0.46
Non-Equity Reserves	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00
Common Equity	-0.92	0.51
Total Shareholders Equity	-0.92	0.51
Accumulated Minority Interest	0.00	0.00
Total Equity	-0.92	0.51
Total Liabilities & Stockholders Equity	0.68	0.97
Book Value Per Share	-0.06	0.03
Tangible Book Value Per Share	-0.06	0.03
Price to Book Ratio	3.76	-
Return on Assets	-175.06	-
Return on Invested Capital	-	-432.43
Quick Ratio	0.39	2.45
Current Ratio	0.39	2.45

Cash flow, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY
Net Income	-4.91	-1.45	-2.20
Other Funds (Non Cash)	3.24	0.03	0.03
Funds from Operations	-1.67	-1.42	-2.17
Extraordinary Item	0.00	0.00	0.00
Changes in Working Capital	-0.92	0.30	-0.17
Cash from Operating Activities	-2.59	-1.11	-2.34
Capital Expenditures	0.00	0.00	0.00
Net Assets From Acquisitions	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00
Purchase or Sale of Investments	-76.99	0.00	0.00
Purchase of Investments	-76.99	0.00	0.00
Sale Or Maturity of Investments	0.00	0.00	0.00
Other Uses	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00
Cash from Investing Activities	-76.99	0.00	0.00
Cash Dividends Paid	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	-	-
Change in Capital Stock	-2.38	0.00	0.00
Repurchase of Common Pref Stock	0.00	0.00	0.00
Sale of Common Pref Stock	-2.38	0.00	0.00
Proceedsfrom Stock Options	-2.38	0.00	0.00
Issuance or Reduction of Debt, Net	0.00	0.75	0.00
Change in Long Term Debt	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00
Net Financing Active Other Cash Flow	86.90	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00
Cash from Financing Activities	84.51	0.75	0.00
Net Change in Cash	4.93	-0.36	-2.34
Free Cash Flow	-2.59	-1.11	-2.34
Deferred Taxes & Investment Tax Credit	-	0.00	0.00

Balance sheet, quarterly

Currency USD, millions
Metric	2026Q3	2026Q2	2026Q1	2025Q3	2025Q2	2025Q1
Cash & Short Term Investments	82.12	0.19	0.25	-	-	-
Short Term Receivables	0.00	0.00	0.00	-	-	-
Inventories	0.00	0.00	0.00	-	-	-
Other Current Assets	0.73	0.01	0.01	-	-	-
Total Current Assets	82.84	0.20	0.26	-	-	-
Net Property, Plant & Equipment	0.00	0.00	0.00	-	-	-
Total Investments and Advances	0.00	0.00	0.00	-	-	-
Intangible Assets	0.00	0.00	0.00	-	-	-
Other Assets	0.00	1.20	0.64	-	-	-
Total Assets	82.84	1.41	0.90	-	-	-
Short Term Debt Incl. Current Port. of LT Debt	0.00	0.87	0.84	-	-	-
Accounts Payable	0.52	1.22	0.61	-	-	-
Other Current Liabilities	0.32	1.10	0.84	-	-	-
Total Current Liabilities	0.84	3.19	2.29	-	-	-
Long Term Debt	0.00	0.00	0.00	-	-	-
Provision for Risks Charges	0.00	0.00	0.00	-	-	-
Other Liabilities	0.00	0.00	0.00	-	-	-
Total Liabilities	0.84	3.19	2.30	-	-	-
Non-Equity Reserves	0.00	0.00	0.00	-	-	-
Preferred Stock - Carrying Value	0.00	0.00	0.00	-	-	-
Common Equity	82.00	-1.78	-1.40	-	-	-
Total Shareholders Equity	82.00	-1.78	-1.40	-	-	-
Accumulated Minority Interest	0.00	0.00	0.00	-	-	-
Total Equity	82.00	-1.78	-1.40	-	-	-
Total Liabilities & Stockholders Equity	82.84	1.41	0.90	-	-	-
Book Value Per Share	5.52	-0.12	-0.09	-	-	-
Tangible Book Value Per Share	5.52	-0.12	-0.09	-	-	-
Full-Time Employees	-	5	-	-	-	-
Price to Book Ratio	3.76	-202.93	-	-	-	-
Return on Invested Capital	-5.98	-	-	-	-	-
Quick Ratio	98.33	0.06	0.11	-	-	-
Current Ratio	98.33	0.06	0.11	-	-	-

Cash flow, quarterly

Currency USD, millions
Metric	2026Q3	2026Q2	2026Q1	2025Q3	2025Q2	2025Q1
Net Income	-4.91	-0.38	-0.48	-0.28	-0.29	-0.36
Other Funds (Non Cash)	3.24	0.03	0.01	-0.01	-0.01	-0.01
Funds from Operations	-1.67	-0.35	-0.47	-0.30	-0.31	-0.37
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	-0.92	0.38	0.12	0.14	0.12	-0.02
Cash from Operating Activities	-2.59	0.03	-0.35	-0.16	-0.18	-0.39
Capital Expenditures	0.00	0.00	0.00	0.00	0.00	0.00
Net Assets From Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	-76.99	0.00	0.00	0.00	0.00	0.00
Purchase of Investments	-76.99	0.00	0.00	0.00	0.00	0.00
Sale Or Maturity of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Other Uses	0.00	0.00	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Investing Activities	-76.99	0.00	0.00	0.00	0.00	0.00
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	-	-	0.00	0.00	0.00
Change in Capital Stock	-2.38	-0.08	0.00	0.00	0.00	0.00
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	-2.38	-0.08	0.00	0.00	0.00	0.00
Proceedsfrom Stock Options	-2.38	-0.08	0.00	0.00	0.00	0.00
Issuance or Reduction of Debt, Net	0.00	0.00	0.00	0.00	0.00	0.00
Change in Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	86.90	0.00	0.00	0.00	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Financing Activities	84.51	-0.08	0.00	0.00	0.00	0.00
Net Change in Cash	4.93	-0.06	-0.35	-0.16	-0.18	-0.39
Free Cash Flow	-2.59	0.03	-0.35	-0.16	-0.18	-0.39

Revenue breakdown

Revenue split	-

Short interest

shares short against float, oldest to newest

Settlement	Of float	Shares short	Float	Avg volume
2026-10-30	0.78%	0.1M	9.5M	160.39K
2026-10-15	0.40%	0.0M	9.5M	179.14K
2026-09-30	0.28%	0.0M	9.5M	202.21K
2026-09-15	0.27%	0.0M	9.5M	220.92K
2026-08-31	0.20%	0.0M	9.2M	268.19K
2026-08-14	0.60%	0.0M	4.3M	267.41K

Option chain

expiry 2026-11-12

Type	Strike	Bid	Ask	Last	IV	Open int	Volume	Delta	Theta	Vega
No option chain for this symbol.

Type

Strike

Bid

Ask

Last

Open int

Volume

Delta

Theta

Vega

No option chain for this symbol.

Latest SEC filings

Filed	Form	Description	Period	Link
2026-11-06	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2026-09-30	SEC
2026-11-06	8-K	Current report	2026-11-06	SEC
2026-10-09	8-K	Current report	2026-10-07	SEC
2026-10-06	4	Statement of changes in beneficial ownership of securities	2026-10-02	SEC
2026-10-06	4	Statement of changes in beneficial ownership of securities	2026-10-02	SEC
2026-10-06	4	Statement of changes in beneficial ownership of securities	2026-10-02	SEC
2026-10-06	4	Statement of changes in beneficial ownership of securities	2026-10-02	SEC
2026-10-06	4	Statement of changes in beneficial ownership of securities	2026-10-02	SEC
2026-10-06	4	Statement of changes in beneficial ownership of securities	2026-10-02	SEC
2026-09-28	3	Initial statement of beneficial ownership of securities	2026-09-21	SEC
2026-09-22	8-K	Current report	2026-09-21	SEC
2026-09-17	10-Q	Quarterly report pursuant to Section 13 or 15(d)	2026-06-30	SEC
2026-09-08	SCHEDULE 13G			SEC
2026-08-19	8-K	Current report	2026-08-19	SEC
2026-08-13	4	Statement of changes in beneficial ownership of securities	2026-08-13	SEC
2026-08-13	4	Statement of changes in beneficial ownership of securities	2026-08-13	SEC
2026-08-13	8-K	Current report	2026-08-13	SEC
2026-08-13	S-8	Initial registration statement for securities to be offered to employees pursuant to employee benefit plans		SEC
2026-08-12	424B4			SEC
2026-08-11	EFFECT	Effectiveness filing by commission order		SEC
2026-08-11	CERT			SEC
2026-08-11	3	Initial statement of beneficial ownership of securities	2026-08-11	SEC
2026-08-11	3	Initial statement of beneficial ownership of securities	2026-08-11	SEC
2026-08-11	3	Initial statement of beneficial ownership of securities	2026-08-11	SEC
2026-08-11	3	Initial statement of beneficial ownership of securities	2026-08-11	SEC
2026-08-11	3	Initial statement of beneficial ownership of securities	2026-08-11	SEC
2026-08-11	3	Initial statement of beneficial ownership of securities	2026-08-11	SEC
2026-08-11	3	Initial statement of beneficial ownership of securities	2026-08-11	SEC
2026-08-10	8-A12B			SEC
2026-08-10	S-1/A			SEC

Insider activity by month

Month	Bought	Buys	Sold	Sells
2026-11	0	0	0	0
2026-10	0	0	0	0
2026-09	0	0	0	0
2026-08	0	0	0	0
2026-07	0	0	0	0
2026-06	0	0	0	0
2026-05	0	0	0	0
2026-04	0	0	0	0
2026-03	0	0	0	0
2026-02	0	0	0	0
2026-01	0	0	0	0
2025-12	0	0	0	0
2025-11	0	0	0	0

Institutional holders

Manager	% owned
GEODE CAPITAL MANAGEMENT, LLC	0.52%
UBS Group AG	0.07%
CITIGROUP INC	0.01%

Funds

Fund	% owned
VANGUARD RUSSELL 2000 INDEX FUND	0.04%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND	0.00%
VANGUARD RUSSELL 2000 VALUE INDEX FUND	0.00%
VANGUARD RUSSELL 3000 INDEX FUND	0.00%

OakChart. VOGX. Cached 15 minutes.

Some panels did not load: ratings, insider, news.